Overview of lupus nephritis management guidelines and perspective from Asia

International Journal of Rheumatic Diseases

Volumn 16, Issue 6, 2013, Pages 625-636

  Mok, Chi Chiu ^a   Yap, Desmond Y H ^b   Navarra, Sandra V ^c   Liu, Zhi Hong ^d   Zhao, Ming Hui ^e   Lu, Liangjing ^f   Takeuchi, Tsutomu ^g   Avihingsanon, Yingyos ^h   Yu, Xue Qing ⁱ   Lapid, Elizabeth A ^c   Lugue Lizardo, Lenrore R ^c   Sumethkul, Vasant ^j   Shen, Nan ^f   Chen, Shun Le ^f   Chan, Tak Mao ^b  

^a TUEN MUN HOSPITAL   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c UNIVERSITY OF SANTO TOMAS   (Philippines)

^d JINLING HOSPITAL   (China)

^e PEKING UNIVERSITY FIRST HOSPITAL   (China)

^f SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^g KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h CHULALONGKORN UNIVERSITY   (Thailand)

ⁱ THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^j MAHIDOL UNIVERSITY   (Thailand)

more..

Author keywords

Asia; Lupus; Nephritis

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT; LEFLUNOMIDE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS;

ASIA; BIOLOGICAL THERAPY; CONSENSUS; DIALYSIS; DISEASE SEVERITY; ETHNIC GROUP; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION; LUPUS ERYTHEMATOSUS NEPHRITIS; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; RACE DIFFERENCE; REVIEW; SHORT COURSE THERAPY; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ASIA; LUPUS; NEPHRITIS;

ADULT; ASIA; ASIAN CONTINENTAL ANCESTRY GROUP; CONSENSUS; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; GUIDELINE ADHERENCE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS NEPHRITIS; NEPHROLOGY; PHYSICIAN'S PRACTICE PATTERNS; RHEUMATOLOGY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84891371215     PISSN: 17561841     EISSN: 1756185X     Source Type: Journal    
DOI: 10.1111/1756-185X.12212     Document Type: Review

References (72)

1. Danchenko N, Satia JA, Anthony MS (2006) Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus 15, 308-18.
2. Osio-Salido E, Manapat-Reyes H (2010) Epidemiology of systemic lupus erythematosus in Asia. Lupus 19, 1365-73.
3. Jakes RW, Bae SC, Louthrenoo W, Mok CC, Navarra SV, Kwon N (2012) Systematic review of the epidemiology of systemic lupus erythematosus in the Asia-Pacific region: prevalence, incidence, clinical features, and mortality. Arthritis Care Res (Hoboken) 64, 159-68.
4. Bomback AS, Appel GB (2010) Updates on the treatment of lupus nephritis. J Am Soc Nephrol 21, 2028-35.
5. Saxena R, Mahajan T, Mohan C (2011) Lupus nephritis: current update. Arthritis Res Ther 13, 240.
6. Austin HA 3rd (1986) Klippel JH, Balow JE, et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 314, 614-9.
7. Steinberg AD, Steinberg SC (1991) Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. Arthritis Rheum 34, 945-50.
8. Gourley MF, Austin HA 3rd, Scott D et al. (1996) Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med 125, 549-57.
9. Illei GG, Austin HA, Crane M et al. (2001) Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 135, 248-57.
10. Bao H, Liu ZH, Xie HL, Hu WX, Zhang HT, Li LS (2008) Successful treatment of class V+IV lupus nephritis with multitarget therapy. J Am Soc Nephrol 19, 2001-10.
11. Tse KC, Lam MF, Tang SC, Tang CS, Chan TM (2007) A pilot study on tacrolimus treatment in membranous or quiescent lupus nephritis with proteinuria resistant to angiotensin inhibition or blockade. Lupus 16, 46-51.
12. Tse KC, Li FK, Tang S, Tang CS, Lai KN, Chan TM (2005) Angiotensin inhibition or blockade for the treatment of patients with quiescent lupus nephritis and persistent proteinuria. Lupus 14, 947-52.
13. Isenberg D, Appel GB, Contreras G et al. (2010) Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study. Rheumatology (Oxford) 49, 128-40.
14. Korbet SM, Schwartz MM, Evans J, Lewis EJ (2007) Collaborative Study G. Severe lupus nephritis: racial differences in presentation and outcome. J Am Soc Nephrol 18, 244-54.
15. Appel GB, Contreras G, Dooley MA et al. (2009) Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 20, 1103-12.
16. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. (2012) KDIGO Clinical Practice Guidelines for Glomerulonephritis. Kidney Int Suppl 2, 139-274.
17. Bertsias GK, Tektonidou M, Amoura Z et al. (2012) Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 71, 1771-82.
18. Hahn BH, McMahon MA, Wilkinson A et al. (2012) American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken) 64, 797-808.
19. Boumpas DT, Austin HA 3rd, Vaughn EM et al. (1992) Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 340, 741-5.
20. Ginzler EM, Dooley MA, Aranow C et al. (2005) Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 353, 2219-28.
21. Houssiau FA, Vasconcelos C, D'Cruz D et al. (2004) Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum 50, 3934-40.
22. Houssiau FA, Vasconcelos C, D'Cruz D et al. (2010) The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis 69, 61-4.
23. Chan TM, Li FK, Wong RW, Wong KL, Chan KW, Cheng IK (1995) Sequential therapy for diffuse proliferative and membranous lupus nephritis: cyclophosphamide and prednisolone followed by azathioprine and prednisolone. Nephron 71, 321-7.
24. Chan TM, Tse KC, Tang CS, Lai KN, Li FK (2005) Long-term outcome of patients with diffuse proliferative lupus nephritis treated with prednisolone and oral cyclophosphamide followed by azathioprine. Lupus 14, 265-72.
25. Mok CC, Ho CT, Chan KW, Lau CS, Wong RW (2002) Outcome and prognostic indicators of diffuse proliferative lupus glomerulonephritis treated with sequential oral cyclophosphamide and azathioprine. Arthritis Rheum 46, 1003-13.
26. Mok CC, Ho CT, Siu YP et al. (2001) Treatment of diffuse proliferative lupus glomerulonephritis: a comparison of two cyclophosphamide-containing regimens. Am J Kidney Dis 38, 256-64.
27. Mok CC, Ying KY, Tang S et al. (2004) Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis. Arthritis Rheum 50, 2559-68.
28. Mok CC, Ying KY, Ng WL et al. (2006) Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide. Am J Med 119 (355), e25-33.
29. Mok CC, Lau CS, Wong RW (1998) Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy. Arthritis Rheum 41, 831-7.
30. Bernatsky S, Ramsey-Goldman R, Clarke AE (2009) Malignancy in systemic lupus erythematosus: what have we learned? Best Pract Res Clin Rheumatol 23, 539-47.
31. Chan TM, Li FK, Tang CS et al. (2000) Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 343, 1156-62.
32. Chan TM, Tse KC, Tang CS, Mok MY, Li FK (2005) Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 16, 1076-84.
33. Ong LM, Hooi LS, Lim TO et al. (2005) Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis. Nephrology (Carlton) 10, 504-10.
34. Tse KC, Tang CS, Lam MF, Yap DY, Chan TM (2009) Cost comparison between mycophenolate mofetil and cyclophosphamide-azathioprine in the treatment of lupus nephritis. J Rheumatol 36, 76-81.
35. Yap DY, Ma MK, Mok MM, Tang CS, Chan TM (2013) Long-term data on corticosteroids and mycophenolate mofetil treatment in lupus nephritis. Rheumatology (Oxford) 52, 480-6.
36. Weng MY, Weng CT, Liu MF (2010) The efficacy of low-dose mycophenolate mofetil for treatment of lupus nephritis in Taiwanese patients with systemic lupus erythematosus. Clin Rheumatol 29, 771-5.
37. Koo HS, Kim YC, Lee SW et al. (2011) The effects of cyclophosphamide and mycophenolate on end-stage renal disease and death of lupus nephritis. Lupus 20, 1442-9.
38. Mak SK, Lo KY, Lo MW et al. (2008) Efficacy of enteric-coated mycophenolate sodium in patients with active lupus nephritis. Nephrology (Carlton) 13, 331-6.
39. Hardinger KL, Hebbar S, Bloomer T, Murillo D (2008) Adverse drug reaction driven immunosuppressive drug manipulations: a single-center comparison of enteric-coated mycophenolate sodium vs. mycophenolate mofetil. Clin Transplant 22, 555-61.
40. Punyawudho B, Lertdumrongluk P, Somparn P et al. (2012) Population pharmacokinetics of mycophenolate mofetil in Thai lupus nephritis patients. Int J Clin Pharmacol Ther 50, 272-80.
41. Lertdumrongluk P, Somparn P, Kittanamongkolchai W, Traitanon O, Vadcharavivad S, Avihingsanon Y (2010) Pharmacokinetics of mycophenolic acid in severe lupus nephritis. Kidney Int 78, 389-95.
42. Kittanamongkolchai W, Rukrung C, Supasiri T et al. (2013) Therapeutic drug monitoring of mycophenolate mofetil for the treatment of severely active lupus nephritis. Lupus 22, 727-32.
43. Houssiau FA, D'Cruz D, Sangle S et al. (2010) Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann Rheum Dis 69, 2083-9.
44. Dooley MA, Jayne D, Ginzler EM et al. (2011) Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 365, 1886-95.
45. Grootscholten C, Ligtenberg G, Hagen EC et al. (2006) Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial. Kidney Int 70, 732-42.
46. Zavada J, Pesickova S, Rysava R et al. (2010) Cyclosporine A or intravenous cyclophosphamide for lupus nephritis: the Cyclofa-Lune study. Lupus 19, 1281-9.
47. Tsakonas E, Joseph L, Esdaile JM et al. (1998) A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group. Lupus 7, 80-5.
48. Moroni G, Doria A, Mosca M et al. (2006) A randomized pilot trial comparing cyclosporine and azathioprine for maintenance therapy in diffuse lupus nephritis over four years. Clin J Am Soc Nephrol 1, 925-32.
49. Chen W, Tang X, Liu Q et al. (2011) Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: a multicenter randomized clinical trial. Am J Kidney Dis 57, 235-44.
50. Tanaka H, Oki E, Tsuruga K, Yashiro T, Hanada I, Ito E (2009) Management of young patients with lupus nephritis using tacrolimus administered as a single daily dose. Clin Nephrol 72, 430-6.
51. Li X, Ren H, Zhang Q et al. (2012) Mycophenolate mofetil or tacrolimus compared with intravenous cyclophosphamide in the induction treatment for active lupus nephritis. Nephrol Dial Transplant 27, 1467-72.
52. Tanaka H, Tsugawa K, Oki E, Suzuki K, Ito E (2008) Mizoribine intermittent pulse protocol for induction therapy for systemic lupus erythematosus in children: an open-label pilot study with five newly diagnosed patients. Clin Rheumatol 27, 85-9.
53. Wang HY, Cui TG, Hou FF et al. (2008) Induction treatment of proliferative lupus nephritis with leflunomide combined with prednisone: a prospective multi-centre observational study. Lupus 17, 638-44.
54. Radhakrishnan J, Moutzouris DA, Ginzler EM, Solomons N, Siempos II, Appel GB (2010) Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis. Kidney Int 77, 152-60.
55. Austin HA 3rd, Illei GG, Braun MJ, Balow JE (2009) Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy. J Am Soc Nephrol 20, 901-11.
56. Swan JT, Riche DM, Riche KD, Majithia V (2011) Systematic review and meta-analysis of immunosuppressant therapy clinical trials in membranous lupus nephritis. J Investig Med 59, 246-58.
57. Szeto CC, Kwan BC, Lai FM et al. (2008) Tacrolimus for the treatment of systemic lupus erythematosus with pure class V nephritis. Rheumatology (Oxford) 47, 1678-81.
58. Yap DY, Yu X, Chen XM et al. (2012) Pilot 24 month study to compare mycophenolate mofetil and tacrolimus in the treatment of membranous lupus nephritis with nephrotic syndrome. Nephrology (Carlton) 17, 352-7.
59. McKinley A, Park E, Spetie D et al. (2009) Oral cyclophosphamide for lupus glomerulonephritis: an underused therapeutic option. Clin J Am Soc Nephrol 4, 1754-60.
60. Li LS, Liu ZH (2004) Epidemiologic data of renal diseases from a single unit in China: analysis based on 13, 519 renal biopsies. Kidney Int 66, 920-3.
61. Tanaka H, Watanabe S, Aizawa-Yashiro T et al. (2013) Long-term tacrolimus-based immunosuppressive treatment for young patients with lupus nephritis: a prospective study in daily clinical practice. Nephron Clin Pract 121, c165-73.
62. Wang S, Li X, Qu L et al. (2012) Tacrolimus versus cyclophosphamide as treatment for diffuse proliferative or membranous lupus nephritis: a non-randomized prospective cohort study. Lupus 21, 1025-35.
63. Takahashi S, Hiromura K, Sakurai N et al. (2011) Efficacy and safety of tacrolimus for induction therapy in patients with active lupus nephritis. Mod Rheumatol 21, 282-9.
64. Yap DY, Ma MK, Tang CS, Chan TM (2012) Proliferation signal inhibitors in the treatment of lupus nephritis: preliminary experience. Nephrology (Carlton) 17, 676-80.
65. Yap DY, Tang CS, Ma MK, Lam MF, Chan TM (2012) Survival analysis and causes of mortality in patients with lupus nephritis. Nephrol Dial Transplant 27, 3248-54.
66. Gaitonde S, Pathan E, Sule A, Mittal G, Joshi VR (2002) Efficacy of isoniazid prophylaxis in patients with systemic lupus erythematosus receiving long term steroid treatment. Ann Rheum Dis 61, 251-3.
67. Liaw YF, Kao JH, Piratvisuth T et al. (2012) Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hep Intl 6, 531-61.
68. Tse KC, Tang CS, Lio WI, Lam MF, Chan TM (2006) Quality of life comparison between corticosteroid- and-mycofenolate mofetil and corticosteroid- and-oral cyclophosphamide in the treatment of severe lupus nephritis. Lupus 15, 371-9.
69. Weening JJ, D'Agati VD, Schwartz MM et al. (2004) The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 65, 521-30.
70. Schwartz MM, Lan SP, Bernstein J, Hill GS, Holley K, Lewis EJ (1993) Irreproducibility of the activity and chronicity indices limits their utility in the management of lupus nephritis. Lupus Nephritis Collaborative Study Group. Am J Kidney Dis 21, 374-7.
71. Hsieh C, Chang A, Brandt D, Guttikonda R, Utset TO, Clark MR (2011) Predicting outcomes of lupus nephritis with tubulointerstitial inflammation and scarring. Arthritis Care Res (Hoboken) 63, 865-74.
72. Rovin BH, Parikh SV, Hebert LA et al. (2013) Lupus nephritis: induction therapy in severe lupus nephritis-should MMF be considered the drug of choice? Clin J Am Soc Nephrol 8, 147-53.